Townsquare Capital LLC Increases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Townsquare Capital LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 219.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,804 shares of the biotechnology company’s stock after purchasing an additional 2,615 shares during the quarter. Townsquare Capital LLC’s holdings in United Therapeutics were worth $1,342,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $25,000. Millstone Evans Group LLC bought a new stake in United Therapeutics during the fourth quarter worth $67,000. MassMutual Private Wealth & Trust FSB boosted its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Jones Financial Companies Lllp grew its stake in United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in United Therapeutics in the 4th quarter valued at $131,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

United Therapeutics stock opened at $284.73 on Friday. The firm has a market capitalization of $12.79 billion, a P/E ratio of 12.50, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a one year low of $233.28 and a one year high of $417.82. The business has a fifty day moving average price of $317.98 and a 200-day moving average price of $349.16.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the company earned $4.36 EPS. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company’s stock, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the company’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $285.16, for a total value of $855,480.00. Following the completion of the transaction, the director now owns 1,750 shares in the company, valued at $499,030. This represents a 63.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 80,500 shares of company stock worth $27,849,960. 11.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on UTHR shares. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.